Drug · CHEMBL1007
GONADORELIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GONADORELIN. Drugs and targets, record CHEMBL1007. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1007
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Gonadorelin decapeptide, Gonadorelina, Gonadoreline, Gonadotropin-releasing hormone
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | Gonadotropin-releasing hormone receptor agonist | AGONIST | https://conductscience.org/library/genes/2798 |
Source ChEMBL
Diseases38
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 38Source Open Targets
See all 38 diseasesTrials65
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 30 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 126 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01607203 | Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist | Phase 4 | 120 | 2015-02-19 | gonadotropin releasing hormone agonist | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01079949 | A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age | Phase 2 | 93 | 2013-02-20 | gonadotropin releasing hormone antagonist | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT03279250 | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | Phase 2 | 86 | 2022-08-10 | gonadotropin-releasing hormone analog | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT02653092 | Reprometabolic Syndrome Mediates Subfertility in Obesity | 84 | 2023-06-01 | gonadotropin-releasing hormone | Its name | ClinicalTrials.gov | |
| NCT01457703 | Reproductive Hormonal Alterations in Obesity | 62 | 2015-03-25 | gonadorelin | Its name | ClinicalTrials.gov | |
| NCT01712230 | Females, Aging, Metabolism, and Exercise | 47 | 2019-11-22 | gonadotropin-releasing hormone agonist | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov | |
| NCT01894581 | Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women | 39 | 2016-07-13 | gonadotropin-releasing hormone | Its name | ClinicalTrials.gov | |
| NCT00586898 | Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle | Phase 2 | 36 | 2016-03-25 | gonadotropin-releasing hormone | Its name | ClinicalTrials.gov |
| NCT04325828 | A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | Phase 2 | 31 | 2022-07-06 | gonadotropin-releasing hormone agonist | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01381016 | Estrogen Sensitivity and Ovulatory Dysfunction in Obesity | 30 | 2015-02-18 | gonadotropin-releasing hormone | Its name | ClinicalTrials.gov |
1 to 10 of 65
See all 65 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BMI ≥30 kg/m2 vs BMI 18-25 kg/m2: serious adverse events | 0 of 29 | 0 of 33 | 62 | NCT01457703 | Trial comparisons |
| Aim 1 vs Aim 2: deaths from any cause | 0 of 13 | 0 of 18 | 31 | NCT02653092 | Trial comparisons |
| Aim 1 vs Aim 2: serious adverse events | 0 of 13 | 0 of 18 | 31 | NCT02653092 | Trial comparisons |
| Obese vs Normal Weight: serious adverse events | 0 of 15 | 0 of 12 | 27 | NCT01894581 | Trial comparisons |
| Experimental vs Control: serious adverse events | 1 of 15 | 0 of 11 | 26 | NCT01381016 | Trial comparisons |
| Younger PMW vs Older PMW: deaths from any cause | 0 of 10 | 0 of 9 | 19 | NCT00386022 | Trial comparisons |
| Younger PMW vs Older PMW: serious adverse events | 0 of 10 | 1 of 9 | 19 | NCT00386022 | Trial comparisons |
| Group 1 (FSH) vs Group 2 (GnRH): deaths from any cause | 0 of 10 | 0 of 6 | 16 | NCT00064987 | Trial comparisons |
| Group 1 (FSH) vs Group 2 (GnRH): serious adverse events | 0 of 10 | 0 of 6 | 16 | NCT00064987 | Trial comparisons |
| Aromatase Inhibitor EFP vs Aromatase Inhibitor LFP: deaths from any cause | 0 of 6 | 0 of 9 | 15 | NCT00351416 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials41
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Psychomotor Vigilance Task | 2 | 0 | ConductCognition |
| Sternberg Memory Scanning | 2 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1007
GET https://conductscience.org/api/drugs/v1/CHEMBL1007/diseases?page=2